Project Grant R01CA308278
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on August 25, 2025, with a completion date of July 31, 2030. This grant funds the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cell therapy for treating small cell lung cancer (SCLC), a disease with exceptionally poor prognosis and limited...
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $730,398 to Sloan-Kettering Institute for Cancer Research through the Cancer Treatment Research program (CFDA 93.395) on September 1, 2025, for a five-year project period concluding August 31, 2030. This Project Grant supports research and development activities designed to advance novel treatment approaches for rectal cancer, with emphasis on organ preservation strategies that minimize patient morbidity. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $418,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) to advance programmable nucleic acid cytometry technology for isolating and analyzing rare cell populations from tumors and tissues. The three-year project, initiated September 1, 2025 and concluding August 31, 2028, focuses on continued development and validation of Programmable Enrichment via RNA...